We show that the majority (88.9%) had a grade 2 or 3 tumor (53.4% of patients had a grade 3 breast cancer, and 35.5% grade 2), 74% had positive hormone receptors, 26% had HER2-overexpressive tumors, and 16.6% had TNBC. The gene discussed is ERBB2; the disease is breast carcinoma.